Notícias

Abstract

BACKGROUND

The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome...

Um bilhão de pessoas em todo o mundo sofrem com males que não têm a visibilidade e as mesmas possibilidades...

Abstract

Background

It is essential to know about immune response levels after booster doses of the two different types of...

No dia 12 de abril, a ABIFINA participou de reunião a convite da Segunda Diretoria da Anvisa (DIRE2) cujo tema...

No dia 13 de abril, a ABIFINA participou da 2ª reunião ordinária do Conselho Nacional de Combate à Pirataria (CNCP),...

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease-19 (COVID-19) pandemic, was identified in late...

Summary

Background

We previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no...

Abstract

BACKGROUND

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus...

Abstract

Cases of deaths due to COVID-19 (COrona VIrus Disease-19) infection are increasing gradually worldwide. Immense research is ongoing to...

Summary

Background

We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases...

Since the identification of the novel coronavirus (SARS-CoV-2), the scientific community has made a huge effort to understand the virus...

Abstract

BACKGROUND

With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2...